Amorfix CEO Dr. Robert Gundel to Present At The New York Society of Security Analysts Annual Conference

TORONTO, Ontario – October 18, 2012 – Amorfix Life Sciences Ltd. announced today that Dr. Robert Gundel, President and CEO, will present a corporate overview of the Company’s diagnostic and therapeutic product pipeline at the New York Society of Security Analysts (NYSSA) Annual Investing in Life Sciences Conference on November 29, 2012.

The NYSSA Life Sciences Conference is an investor forum where executives from some of the most innovative small- and micro-cap companies in the biotech sector discuss their progress with trials and their plans to develop, research, and market important new drugs, diagnostics and delivery technologies. Conference presentations focus on the investment outlook for the sector as well as the prospects for each company in separate 30-minute presentations from senior management.

The Amorfix Life Sciences corporate overview is scheduled for 2:00 pm EST on November 29, 2012.


About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for Alzheimer’s disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.


The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.


- 30 -


ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life Sciences Ltd.